Search

Durvalumab

[A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage

Telotristat ethyl

Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo.

Vadadustat

[L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371]

Sotagliflozin

[L39739] On March 22, 2022, the marketing authorization of sotagliflozin for the treatment of type 1 diabetes mellitus was withdrawn by the EMA due to commercial reasons.

Dasiglucagon

[L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE.

Sodium phosphate, dibasic

Grapiprant

[L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836]

Eftrenonacog alfa

It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.

Aducanumab

[A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing

Ad5-nCoV

[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906